Drug intelligence / Profile preview

Cresere

Development stage: Preclinical
Lead developer: Synergistic Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

**Cresere** is a patented topical prescription pharmaceutical formulation developed and manufactured by Synergistic Therapeutics for hair loss and promotion of hair growth. The company states that the formulation contains finasteride plus undisclosed proprietary compounds and is intended to suppress scalp inflammation, increase local blood flow, and enhance scalp penetration. Finasteride inhibits steroid 5-alpha-reductase, reducing formation of dihydrotestosterone, a mediator of androgen-dependent hair-follicle miniaturization. The identities and pharmacology of Cresere's additional proprietary constituents have not been publicly disclosed. ([synergistictherapeutics.com](https://www.synergistictherapeutics.com/cresere))

Brand names: Cresere

Targets

SRD5A2 (Steroid 5-alpha-reductase type II)

Beyond the preview

Go deeper on Cresere.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cresere.

Explore the full profile